Orion Pharma Animal Health - a part of Orion Corporation - and Vetoquinol announces their collaboration regarding the distribution of Orion Pharma Animal Health Sedatives product family alpha 2 -agonists and antagonist Dexdomitor®, Domitor® and Domosedan® and Antisedan®. Vétoquinol becomes distributor in selected European countries of these Orion Sedative products.
The collaboration between the companies is effective as of 1 January 2015 and Vetoquinol is responsible for marketing the sedatives to customers in United Kingdom, Germany, France, Ireland, The Netherlands, Belgium, Luxembourg and Italy.
Niclas Lindstedt, Vice President of Orion Pharma Animal Health commented:
"Orion Pharma Animal Health foresees that this new alliance with a dedicated and recognized partner will further strengthen the position with customers of the well accepted Orion sedatives range. Vétoquinol has a particularly strong focus on the companion animal pain and sedation segments in the concerned countries.
Matthieu Frechin, CEO of Vetoquinol commented:
"The inclusion of the sedative products from Orion Pharma Animal Health in our pain and surgery product range will further reinforce our offer to our customers; it is a an additional proof of our willingness to be a partner of choice for all vet surgeons in the field of pain and anesthesia."
About Dexdomitor®, Domitor®, Domosedan® and Antisedan®
Orion Pharma Animal Health proprietary sedatives range include products Dexdomitor® 0,5 mg/ml, Dexdomitor® 0,1 mg/ml, Domitor®, Antisedan®, Domosedan® and Domosedan Gel®. The Sedative range products are Orion Corporation proprietary products and they belong to the alpha 2 -agonists and antagonist segment. The latest additions to the Orion Pharma Animal Health Sedatives segment are Domosedan Gel® for sublingual dosing on detomidine for horses from year 2010 and Dexdomitor® 0,1 mg/ml for accurate and precise dosing of dexmedetomidine for small sized dogs and cats from year 2012.
About Vetoquinol
Vétoquinol is a leading global player in the animal health sector serving both the livestock (cattle and pigs) and pet (dogs and cats) markets. A family owned, pure player, Vétoquinol designs, develops and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region.
Since its foundation in 1933, Vétoquinol has pursued a strategy combining innovation with geographical diversification. The Group's hybrid growth is driven by the reinforcement of its product portfolio coupled with acquisitions in high potential growth markets. Vétoquinol employs 1988 people world-wide.Vétoquinol has been listed on NYSE Euronext Paris since 2006 (symbol: VETO).
For more information: www.vetoquinol.com.
Contact person:
Orion Pharma Animal Health
Mr. Niclas Lindstedt, Vice President
Email: niclas.lindstedt@orionpharma.com
Tel. +358 50 966 4116
Publisher:
Orion Corporation
http://www.orion.fi/
Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion developes inhaled Easyhaler® pulmonary drugs.
Orion's net sales in 2014 amounted to EUR 1,015 million and the Company had about 3,500 employees. Orion's A and B shares are listed on NASDAQ Helsinki.